window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : May 1, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

AI drug discovery

  • Artificial Intelligence,Genomics and sequencing,Metabolic Diseases,Obesity,Research & Development

    Insitro completes first AI-enabled human genetics study of brown adipose tissue, identifies differentiated obesity targets

    insitro has completed what it says is the first population-scale [...]

    February 3, 2026
  • Artificial Intelligence,Biotech,Drug Development,Mergers & Acquisitions,Technology and platforms

    CombinAbleAI to be acquired by insitro to expand AI drug discovery platform

    AI therapeutics company, insitro, has agreed to acquire CombinAbleAI in [...]

    January 14, 2026
  • Artificial Intelligence,Drug Development,European biotech,Partnerships & Funding,Technology and platforms

    FluoSphera raises €1.23 million to scale human-based preclinical testing platform

    Swiss biotech startup FluoSphera has raised €1.23 million (CHF 1.15 [...]

    January 12, 2026
  • Biotech,Global health,Research & Development,Technology and platforms

    ICON 2025 global biotech survey shows China leading innovation and highlights Western opportunities

    ICON plc has released findings from its 2025 global biotech [...]

    December 11, 2025
  • Chronic diseases,Drug Development,Genomics and sequencing,Pharmaceuticals and therapeutics,Research & Development

    Ochre Bio and GSK complete research phase with large-scale human liver genomics datasets

    Ochre Bio has completed the research phase of its collaboration [...]

    November 18, 2025
  • Artificial Intelligence,Biotech,Chronic diseases,Partnerships & Funding,Pharmaceuticals and therapeutics,Research & Development,Single Cell analysis,Technology and platforms

    Immunai signs $85 million AstraZeneca deal to advance inflammatory bowel disease target

    Immunai has signed an agreement worth up to $85 million [...]

    October 16, 2025
  • Artificial Intelligence,Clinical Development,Clinical studies,Drug Development,Neurosciences,Pharmaceuticals and therapeutics,Research & Development

    Leading global experts join judging panel for £7.5m Longitude Prize on ALS

    A panel of international leaders in neuroscience, artificial intelligence and [...]

    September 26, 2025
  • Artificial Intelligence,Cell & Gene Therapy,Drug Development,Research & Development,Technology and platforms

    AISB Network expands Federated OpenFold3 initiative with three new pharma contributors

    The AI Structural Biology (AISB) Network, powered by Apheris GmbH, [...]

    September 23, 2025
  • Artificial Intelligence,Biologics & Biosimilars,Drug Development,Movers & Shakers,Pharmaceuticals and therapeutics,Technology and platforms

    DaltonTx raises £4 million seed financing to build AI-enabled drug discovery platform

    DaltonTx, a UK-based technology company, has exited stealth mode and [...]

    September 23, 2025
  • Artificial Intelligence,Drug Development,Partnerships & Funding,Technology and platforms

    Lilly launches $1 billion TuneLab AI platform to boost biotech drug discovery

    Eli Lilly and Company has launched TuneLab, a new artificial [...]

    September 10, 2025
Previous123Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Neomorph raises $100 million to advance NEO-811 Phase 1/2 cancer trial and molecular glue degrader pipeline
    Categories: Biotech, Clinical Trials, Drug discovery, Funding, Oncology, Partnerships & Funding, Pharmaceuticals and therapeutics, Research & Development, Technology and platforms
  • NICE expands Lokelma access for hyperkalaemia after draft recommendation
    Categories: Cardiovascular diseases, Chronic diseases, Market Access & Commercialization, Pharmaceuticals and therapeutics, Regulatory Affairs
  • Oncodesign expands ARRONAX deal to secure astatine-211 supply for radiotherapy research
    Categories: CDMOs & Manufacturing, Drug Development, European biotech, Logistics and distribution, Oncology, Partnerships & Funding, Supply Chain & Logistics
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top